CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.60
+0.15 (+10.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.45
Open1.45
Bid1.35 x 900
Ask1.60 x 3100
Day's Range1.45 - 1.60
52 Week Range1.25 - 2.95
Volume41,802
Avg. Volume12,871
Market Cap39.014M
Beta0.98
PE Ratio (TTM)N/A
EPS (TTM)-1.10
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Drs. William Ludlam and Asi Haviv will present at the 12th Acromegaly Consensus Conference on June 19th in Prague. Pharmacologic treatment of acromegaly includes chronic therapy with parenteral Somatostatin Receptor Ligands (SRLs), including octreotide.

  • GlobeNewswirelast month

    Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has achieved 50% patients randomized in its international Phase 3 clinical trial, referred to as “CHIASMA OPTIMAL” (Octreotide capsules vs. Placebo Treatment In MultinationAL centers), of its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. The Company also announced CHIASMA OPTIMAL has achieved the FDA-required minimum of 10 patients randomized from the United States. Chiasma expects CHIASMA OPTIMAL to complete randomization by the end of 2018 and anticipates the release of top-line data from this trial in Q4 2019.

  • GlobeNewswire2 months ago

    Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) to redefine certain secondary endpoints of its recently initiated CHIASMA OPTIMAL Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. Chiasma has received a Special Protocol Assessment (SPA) Agreement Modification letter from the FDA to formalize these changes.

  • Associated Press2 months ago

    Chiasma: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 29 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.45. A year ago, they were trading at $1.60. _____ ...

  • GlobeNewswire2 months ago

    Chiasma Reports First Quarter 2018 Results

    WALTHAM, Mass., May 10, 2018-- Chiasma, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results ...

  • Associated Press4 months ago

    Chiasma reports 4Q loss

    The Waltham, Massachusetts-based company said it had a loss of 25 cents per share. Losses, adjusted for restructuring costs, came to 21 cents per share. In the final minutes of trading on Tuesday, the ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

    Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...

  • Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately
    Simply Wall St.4 months ago

    Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately

    Examining Chiasma Inc’s (NASDAQ:CHMA) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...

  • Associated Press8 months ago

    Chiasma reports 3Q loss

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. In the final minutes of trading on Thursday, the company's shares hit $2. A year ago, they were trading at ...

  • Is Chiasma Inc’s (CHMA) CEO Pay Fair?
    Simply Wall St.8 months ago

    Is Chiasma Inc’s (CHMA) CEO Pay Fair?

    Mark Fitzpatrick has been at the helm as CEO of Chiasma Inc (NASDAQ:CHMA), which has grown to a market capitalization of USD$51.16M. Recognizing whether CEO incentives are aligned with shareholdersRead More...

  • Associated Press11 months ago

    Chiasma reports 2Q loss

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. In the final minutes of trading on Thursday, the company's shares hit $1.40. A year ago, they were trading ...